Growth factor-mobilized peripheral blood stem cells (PBSCs) engraft rapidly in myeloablated recipients compared to conventional BM, but this procedure also mobilizes mature lymphocytes and monocytes which can impact immune reconstitution and GVHD. Hence, we serially evaluated immune reconstitution and cytokine expression in PBSCT recipients in the first year. 
Allogeneic bone marrow transplantation (BMT) is curative therapy for many malignant hematologic and genetic disorders. [1] [2] [3] Growth factor-mobilized allogeneic PBSCT, by providing more CD34
+ stem cells compared to bone marrow, results in an advantage for recipients with earlier neutrophil and platelet recovery thus decreasing transfusion requirements and duration of hospital stay. [4] [5] [6] [7] [8] [9] [10] [11] [12] The prolonged intense supportive care when awaiting engraftment that is necessary following conventional BMT as well as the morbidity and logistics of harvesting marrow from normal donors under general anesthesia can be avoided by using cytokine-mobilized allogeneic PBSC.
The lymphocyte and monocyte composition of cytokinemobilized peripheral blood products as well as their cellular function is different from bone marrow and resting peripheral blood. [13] [14] [15] [16] As analyzed at our institution, compared to resting peripheral blood, monocytes are increased four-fold in the peripheral blood of normal allogeneic donors mobilized with G-CSF. 17 CD19 + B cells increase three-fold and CD3 + T cells are increased two-fold. This increase is reflected as proportionate increases in CD4 + and CD8 + T cell subsets thus maintaining a normal CD4:CD8 ratio. 17, 18 In addition to increases in the absolute numbers of B and T cells, NK cells increase 150% from baseline after G-CSF mobilization. Other recent studies have confirmed the observations that growth factor promotes the mobilization of lymphocytes and NK cells in normal allogeneic donors.
Korbling et al described a 16-fold increase in CD3
+ cells, a 13-fold increase in CD4 + T cells (increased CD45RO
+ memory cells as well as ␥␦ cells has been described by Mills et al) and 27.4-fold increase in CD8 + T cells after peripheral blood growth factor mobilization compared to bone marrow harvests. An 11-fold increase in CD19
+ B cells and a 19.4-fold increase in CD56
+ NK cells was also noted. 19 Furthermore, autologous stem cell transplantation results in significantly more rapid recovery of monocytes, NK cells and naive CD4 + T lymphocytes, which then translates into early immune function recovery compared to delayed reconstitution especially of naive CD4
+ T lymphocytes in conventional BMT. 20, 21 Therefore, it is conceivable that the infusion of stem cell products with such altered numbers of lymphocytes, monocytes and NK cells in an allogeneic setting could affect post transplant immune reconstitution as well as the extent and severity of GVHD. Conversely, immune reconstitution which is crucial following transplantation is closely linked to the development and treatment of GVHD and influences infectious complications. [22] [23] [24] [25] We evaluated immune reconstitution in the first year in recipients following allogeneic PBSCT from HLA-matched family donors for various resistant hematologic malignancies. Measurement of neutrophils, monocytes, B cell, NK cell and T cell subset engraftment and function were performed serially for 1 year post transplant. Additionally, constitutive post-transplant lymphokine mRNA expression patterns were determined in a subset of patients using RT-PCR.
Materials and methods

Recipient population demographics
These transplants and studies were performed after informed consent was obtained under protocols approved by the Human Studies Committee and Institutional Review Board of Washington University. Recipients with resistant hematologic malignancies who received PBSCT from HLAmatched sibling donors were the subjects of this study. Stable donor chimerism (Ͼ95% donor cells) was confirmed by serial VNTR analyses on bone marrow aspirates between days 50 and 120. Recipients with graft rejection, recurrent malignancy or severe post-transplant complications and organ failure requiring intensive care and lifesupport were excluded. Thirty patients (20 males and 10 females; mean age 39 years; range 14-64 years) were evaluated at different time points post PBSCT. Indications for PBSCT as well as recipient demographics are summarized in Table 1 . All recipients were heavily pretreated with multiple cycles of standard chemotherapy with or without radiation using established protocols for their disease. No recipient underwent splenectomy prior to transplant. Since recipients were treated with PBSCT for six hematologic diseases, combination chemotherapy varied according to the lymphoma or leukemia treated. Frontline standard therapy was used in all these diseases and transplants were undertaken for poor response and high risk of relapse.
All donors were mobilized with 10 g/kg/day of G-CSF for 4 days prior to leukapheresis. Twenty liter leukapheresis Table 1 Indications for PBSCT in patient population studied for immune reconstitution 26 Unmanipulated allogeneic PBSCs were infused into allogeneic transplant recipients on day 0. Twenty-six recipients were conditioned with total body radiation (TBI) 175 cGy × 6 doses, etoposide 30 mg/kg × 1 dose and cyclophosphamide 50 mg/kg × 2, and four recipients with cyclophosphamide 60 mg/kg × 2 and busulphan 1 mg/kg × 16 doses (due to inability to receive TBI). Cyclosporine 3 mg/kg by continuous intravenous infusion was commenced on day Ϫ1 in all recipients prior to PBSC infusion. Cyclosporine levels were maintained at 250-350 ng/ml for 100 days, and gradually tapered or continued based on recipient GVHD status. Steroids (0.5 mg/kg methylprednisolone) were commenced on day +7 post transplant, increased to 1 mg/kg on day +14 and tapered between days 28 and 56 in the absence of GVHD. No recipient received immunoglobulin infusions in the post-transplant period.
White cell engraftment (ANC Ͼ500/l) occurred at a median of 9 days, platelets (Ͼ20 000/l) at a median of 10 days. Eleven of 30 (37%) patients developed grades II-IV acute GVHD graded as described by Glucksberg et al; 27 12% developed grade III-IV disease. Skin was the commonest site of significant involvement. Twenty-one of 30 (72%) developed chronic GVHD at a median of 120 days graded as per Shulman et al 28 and included extensive skin, gut and liver involvement which necessitated continuation of immunosuppressive therapy. Eight of 10 (80%) recipients evaluated at 1 year post transplant continued to receive prophylaxis/treatment for GVHD with CsA and steroids. Isolated cGVHD was uncommon. The actuarial risk of chronic GVHD in survivors at day +180 was 92%. The development of acute or chronic GVHD did not correlate with the numbers of CD34 + , CD4 + , CD8 + , CD3 + or mononuclear cells/kg. 29 A high incidence of clinical extensive chronic GVHD (relative risk 2.37 at 2 years) has also been reported in allogeneic PBSCT recipients by Storek et al. 30 
CMV infection
CMV viremia and infection post PBSCT has been reported from our institution by DiPersio et al. 31 Twenty-two of 30 (74%) of PBSCT recipients were at risk for CMV infection (seropositive donor 18% and/or recipient 56%). Nineteen of 30 (62%) developed CMV viremia as measured by shell vial cultures at a median of 34 days, 25% had second episodes and 8.3% had third episodes and 5.4% developed CMV disease.
Cell preparation
PBMCs were separated from heparinized blood on FicollHypaque density gradients (Pharmacia Biotech, Uppsala, Sweden). Mononuclear cells were washed twice with phosphate-buffered saline (PBS) (Sigma, St Louis, MO, USA) and suspended in RPMI-1640 (Sigma) supplemented with 2 mm l-glutamine, 1 mm sodium pyruvate, 25 mm Hepes, 100 U/ml penicillin and 100 g/ml streptomycin and 15% fetal bovine serum (Biocell Laboratories, Rancho Dominguez, CA, USA).
Normal control cells were obtained from donors prior to mobilization with growth factors and were used for all control assays described. These cells were evaluated as normal controls since immune reconstitution post PBSCT was a reflection of the function of these cells following engraftment in PBSCT recipients whose intrinsic cells had been effectively ablated. Since recipients were only evaluated if they were a donor chimera and immunologic status was a donor-derived function, recipient immune functions prior to transplant were not evaluated. It is assumed that high-dose chemotherapy in recipients prior to transplant would suppress immune functions and immune reconstitution with donor cells was necessary to normalize these functions again.
Lymphocyte subset analysis (immunofluorescence studies)
The total number of lymphocytes, neutrophils and monocytes were calculated from peripheral blood using a Coulter STKS Automated Hematology Analyzer. Lymphocyte subsets were estimated on peripheral blood samples. 
Proliferation assays
Normal control and patient PBMCs were suspended in culture medium at 1 ϫ 10 6 cells/ml, plated in triplicate in flatbottomed 96-well microtiter trays at 10 5 cells per well and cultured at 37°C with optimum concentrations of mitogens (PHA 10 g/ml or anti-CD3 150 ng/ml) for 72 h or a mixture of 2 ϫ 10 4 irradiated (50 Gy) allogeneic lymphoblastoid cell lines (LCLs) (allogeneic MHC stimulators) for 5 days. PHA was obtained from Sigma and anti-CD3 from Orthobiotech (Raritan, NJ, USA). 
In vitro immunoglobulin (Ig) production by B cells
Twenty PBSCT recipients between 1 and 3, 4 and 6, 7 and 9 and 10 and 12 months were evaluated for Ig secretion, five at each time point. Five normal controls were simultaneously evaluated. One hundred thousand recipient PBMCs were cultured in 0.1 ml of medium containing 15% FCS with 10 g/ml of pokeweed mitogen (PWM) in 96-well culture plates. Fifty microliters of supernatant was harvested after 6 days of culture at 37°C and Ig secretion was determined using a sandwich ELISA technique. 32 Supernatant was harvested at 6 days since standard protocols indicate that maximum polyclonal Ig secretion occurs at 6-7 days following T-dependent B cell stimulation with PWM. 33 Control PBLs were subjected to similar stimulation with PWM and harvested supernatant was also tested for total Ig secretion. Briefly, ELISA plates were coated overnight with 0.1 ml/well of optimally diluted affinity purified antibody to human Igs (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). After blocking with 3% BSA (bovine serum albumin), appropriately diluted patient and control samples as well as the standard Ig dilutions were incubated for 1 h at room temperature following the addition of optimally diluted peroxidase-conjugated rabbit affinity purified anti-human Ig (Cappel, Durham, NC, USA). Plates were washed with PBS-Tween buffer. Microwell peroxidase substrate (Kpl) was added to the plates and optical density read out at 410 nm. Test and control sample Ig concentrations were determined using curves generated from standards. Irradiated control cells produced Ͻ1 ng/ml of Ig.
Cytokine mRNA expression by RT-PCR and Southern analysis
Constitutive mRNA expression in PBMCs was determined in two groups, nine recipients 0-6 months and 13 recipients 7-12 months post PBSCT, using the methods of Sundaresan et al. 34 RNA was extracted from 5 to 10 ϫ 10 6 unstimulated PBMCs. Five micrograms of RNA were reverse transcribed and amplification of cytokine-specific cDNA fragments was accomplished by 30 cycles of PCR, adding 0.5 l of cDNA dNTP mixture, DMSO, 10 × buffer (Geneamp PCR Buffer, Cetus, Norwalk, CT, USA), Taq DNA Polymerase (Promega, Madison, WI, USA), and the 5Ј-and 3Ј-specific primers for IL-2, IL-4, IL-10, TNF␣, IFN␥ and ␤-actin (control). Annealing temperature for ␤-actin was 58°C and 54°C for other cytokines. mRNA from normal control PBMCs stimulated for 12 h with 10 g/ml of PHA served as positive controls. Six unstimulated volunteer donor PBMCs as well as sterile water substituted for template cDNA were also used as controls. ␤-actin was used as positive control for PCR reactions. Twenty microliters of each PCR product were subjected to electrophoresis on a 2% agarose gel (Midwest Scientific, Valley Park, MO, USA) with ethidium bromide staining and blotted on to nylon membranes (Genescreen Plus, NEN Research Products, Boston, MA, USA). After pre-hybridization for 2 h at 42°C, the blots were probed with 32 P-labeled specific oligonucleotide probes. Radiographs were generated by exposure to X-ray film (Kodak X-OMAT XAR-5; Sigma) at Ϫ70°C for 48 h.
Intracellular calcium measurements
Five million normal control or recipient PBMCs were activated from their normal peripheral resting state by incubating overnight in 5.0 ml culture medium with 10 g/ml PHA. Two million cells were used to measure the Ca ++ influx in each experiment. Cells were suspended in Hank's balanced salt solution (HBSS) without Ca 2+ and Mg 2+ containing 0.5% BSA (Sigma) and incubated for 30 min at 37°C with 1 m fura-2-acetomethyl ester (Molecular Probes, Eugene, OR, USA). Intracellular calcium measurements were conducted using the method described by Naziruddin et al. 35 Cells were washed twice with HBSS, resuspended in 1.0 ml HBSS with 0.5% BSA and incubated for 10 min with 5 g anti-CD3 (Orthobiotech, Raritan, NJ, USA) or 5 g isotype-matched negative control (MOPC) on ice. Fluorescence changes in HBSS containing Ca 2+ (CaCl 2 140 mg/l) and Mg 2+ (MgCl 2 97.7 mg/l) were monitored with a F-2000 Hitachi Fluorescence Spectrophotometer (Danbury, CT, USA), using 340-and 380-nm excitation and 510-nm emission wavelengths. Goat anti-mouse Ig as a cross-linking agent was added at 60 s from the start of fluorescence measurement. Sixty seconds later, cells were lysed with 1% Triton followed by calcium chelation with 0.1 m EDTA to end the reaction. Changes in intracellular Ca 2+ i concentrations in the nm range were calculated from individual flux patterns as described by Grynkiewicz et al. 36 Thirteen normal volunteers served as controls. Group one consisted of 11 patients, 1-6 months post PBSCT and group two had six patients, 7-12 months post transplant as described in Figure 3 .
NK-mediated cytolysis
K562 cells (NK cell targets) were labeled for 60 min with 250 Ci of 51 Cr (ICN). After washing three times, 10 3 K562 cell targets were plated in triplicate in 96-well plates and incubated with 2.5 ϫ 10 4 PBMCs (E:T ratio 25:1) for 6 h prior to harvest. 51 Cr release was measured using a microbeta system (Wallac). Spontaneous lysis was calculated from targets incubated in medium and maximum lysis from targets incubated with 1% Triton. Percent-specific lysis was calculated using the following formula: experimental release Ϫ spontaneous release divided by the maximum release Ϫ spontaneous release × 100%. Eight normal controls, 16 recipients between 1 and 3 months, eight between 4 and 6 months, nine between 7 and 9 months and eight between 10 and 12 months were evaluated for NK function.
Statistical analysis
Proliferation and NK assays were subjected to the one-way ANOVA test with Tukey's simultaneous confidence intervals. Pair-wise differences in stimulation indices (SIs) between controls and recipients at different time points were evaluated for each assay in addition to differences in control and recipient NK-mediated lysis. Significant observations (P Ͻ 0.05) are indicated by asterisks on each figure. Lymphocyte subset numbers as well as immunoglobulin assays and intracellular calcium concentrations were compared with control values and analyzed for significance using the t-test.
Results
Engraftment of CD4 + T cells, NK and B cells remains low through the first year
Lymphocyte engraftment was measured by immunofluorescence studies on peripheral blood at 1, 3, 6 and 12 months and is presented in Table 2 . Premobilization mean lymphocyte and lymphocyte subset numbers in normal donors are considered as control values. CD3
+ cells approached normal levels between 9 and 12 months primarily due to an increase in CD8 + T cell numbers. Monocyte numbers remained stable post transplant although an initial rise in granulocytes was noted. The general trend was for all subsets to gradually increase with the exception of NK cells. However, except for CD8 + T cells which increased above mean control values by 6 months, other lymphocyte subset numbers never reached normal range. CD8 + T cells increased above control levels by 3 months and continued to rise. This increase accounted for the increase in total lymphocyte numbers in the presence of persistently low numbers of CD4 + T cells. CD4 + T cells remained significantly (P Ͻ 0.05) lower than control levels even at 12 months. The CD4/CD8 T cell ratio was inverted at 1 month and stayed inverted through the first 12 months of this analysis. CD19
+ B cells gradually increased through the first year but did not reach control levels even at 12 months and remained significantly low. CD56 + /16 + NK cell numbers were higher (1.8 ϫ 10 5 /ml) ( Table 2 ) at 1 month (although less than control levels) but subsequently continued to decrease such that their numbers were significantly less than 30% of pre-mobilization donor levels (controls) at 12 months post transplant (0.7 vs 2.7 ϫ 10 5 /ml) (P Ͻ 0.05).
T cell proliferation remains impaired in the first year post PBSCT
T cell function was evaluated by proliferation in response to PHA, anti-CD3, and allogeneic MHC antigen stimulators. Recipients were evaluated at 0-3 months, 4-6 months, 7-9 months and 10-12 months post PBSCT and compared to normal donor controls. Figure 1 shows proliferation of PBMCs to PHA and anti-CD3 compared to proliferation in control PBLs. Proliferation in response to PHA and anti-CD3 was significantly (P Ͻ 0.05) less than in controls at all time points tested. Similarly, the ability of recipient PBMCs to proliferate in response to mixed allogeneic radiated LCLs was 4-10 times lower than in control cells (Figure 2 ). The mean SI in normal controls was 13.26. In the study population, evaluated at 1-12 months post PBSCT, SIs ranged between 1.71 and 4.07. This difference in the stimulation index was significant (P Ͻ 0.05) at 1-3 months and 7-9 months. Sample numbers were too small to comment upon in the other two groups evaluated at 4-6 months and 10-12 months although the stimulation indices were similar. Overall, proliferation of engrafted T cells to mitogens and allogeneic MHC was impaired at all time points in the first post transplant year, with no demonstrable recovery of function during the interval tested. Serial evaluation of proliferation to PHA in three index PBSCT recipients to demonstrate the lack of recovery of proliferative function is shown in Figure 1a .
Intracellular calcium measurements following recipient T cell activation with anti-CD3 is comparable to control cells
Since T cell proliferation assays were markedly depressed, engrafted cells were evaluated for their ability to respond to stimulation with anti-CD3 with subsequent increase in intracellular calcium levels. Calcium concentrations calculated by fluorescence changes after 12 h activation with PHA and cross-linking with anti-CD3 are shown in Figure  3 and compared with levels measured in similar numbers of normal cells (2 ϫ 10 6 ). The intracellular calcium concentration was calculated from baseline and peak levels of response following cross-linking. Mean and standard deviations were calculated from each group and significant differences evaluated. Intracellular calcium levels tended to decrease when evaluated at 6-12 months post PBSCT but the decrease was not statistically significant (P = 0.07).
Thus activated engrafted cells were capable of responding to stimulation by increasing intracellular calcium concentrations and showed no major changes from baseline control levels.
Immunoglobulin production by B cells following in vitro stimulation recovers early following PBSCT
The functional ability of engrafted B cells to secrete Ig on stimulation with PWM was measured by harvesting culture supernatants of PBMCs incubated for 6 days with 10 g/ml of PWM at 1-3, 4-6, 7-9 and 10-12 months post transplant ( Figure 4) . No difference was noticed in total Ig production in the recipients studied (range 20.6-193.3 ng/ml) when compared with six controls (31.5-90.6 ng/ml). Immunoglobulin levels tended to be higher than control levels when measured between 9 and 12 months post PBSCT but the difference was not significant (P = 0.07).
NK cell-mediated lysis of target cells is impaired significantly in the first 12 months post PBSCT
The ability of engrafted NK cells to lyse susceptible targets (K562) was measured as an assay of NK cell function. NK assays are shown as percent lysis of K562 targets by PBMCs at E:T ratios of 25:1 ( Figure 5 ). Mean control lysis was 26.72%. Mean NK-mediated lysis was 4.82% at 3 months, 7.1% at 6 months, 12.48% at 9 months and 7.08% at 12 months which was significantly (P Ͻ 0.05) less than control levels at all time points as indicated in Figure 5 . Although minimum improvement was seen after 3 months, NK function continued to remain significantly low throughout the first year. Three recipients are shown serially followed in Figure 5a to demonstrate the lack of recovery of NK cell function.
Constitutive cytokine mRNA expression patterns by peripheral blood mononuclear cells changed during the first year
Since different cytokines are associated with acute and chronic GVHD, resting recipient PBMCs were analyzed for expression of IL-2, IL-4, IL-10, IFN␥ and TNF␣ mRNA by RT-PCR analysis ( Figure 6 ). Nine recipients were evaluated 1-6 months post transplant. Of these, seven (77%) strongly expressed IL-10 and three expressed IL-4. Three of the nine demonstrated weak expression of IL-2 and four others showed a weak message for IFN␥. TNF␣ was strongly expressed by all recipients. Of the 13 recipients tested 7-12 months post transplant, six strongly expressed IFN␥ and five expressed IL-2. Only four recipients (30%) from this group expressed IL-10 and three expressed IL-4. All recipients but one continued to express TNF␣ (Table  3) . When recipient PBLs were stimulated for 12 h with PHA, all cytokines were strongly upregulated and easily detectable in both groups supporting appropriate responses to stimulation. Positive controls were normal PBLs stimu- lated for 12 h with PHA (10 g/ml) following which all cytokines tested were strongly expressed. Five of six normal unstimulated control PBMC samples failed to show the presence of any of the cytokines, one was positive for the presence of IL-2. All were positive for ␤-actin which was used as a positive control for all assays ( Figure 6 ). 
Discussion
The use of cytokine-mobilized peripheral blood as a source of stem cells in the autologous transplant setting has been superior to BMT in achieving early engraftment of neutrophils and platelets thus decreasing the duration of hospitalization and blood product utilization in the post-transplant period. Such transplants which were predominantly undertaken as autologous rescue following high-dose chemotherapy proved to be safe and effective. In light of the ease, efficacy and cost saving associated with PBSCT, growth factors (G-CSF and GM-CSF) have now been used to mobilize stem cells from peripheral blood of normal allogeneic transplant donors. 19, [37] [38] [39] Following conventional allogeneic BMT, 40-85% of recipients develop significant acute GVHD depending on the level of HLA identity. The development of GVHD is dependent on the immune and cytokine profiles in the recipient. 27, 39 Immune reconstitution is also an important component of a successful allogeneic transplant, since viral, fungal and bacterial infections contribute significantly to morbidity and mortality in recipients. Immune reconstitution has been carefully evaluated in recipients of allogeneic bone marrow with and without T depletion. [41] [42] [43] [44] [45] Quantitatively, cellular components of the immune system return to normal levels in 4-6 months following conventional BMT with the exception of CD4 + T cell and B cell engraftment which is often delayed. 42, 43 Naive CD45RA cell numbers are depressed following BMT for over a year, with early recovery of memory CD45RO
+ cells suggesting engraftment of mature cells from the donor/recipient rather than lymphocytes arising from maturing stem cells. 20, 21 Qualitatively, NK and LAK functions have been reported to normalize very early in the first 2-3 months. [45] [46] [47] T cell proliferation as well as immunoglobulin production remains impaired usually until the second half of the first year post transplant. Yamagami et al 48 further characterized T cell immune defects following conventional BMT and found that 40% of recipients had blunted calcium flux responses after CD3 stimulation and was able to attribute this predominantly to decreased numbers of responding cells. This immune deficient picture is associated with a reversed CD4:CD8 T cell ratio in the first year. However, immune functions return to baseline levels at about 12 months in the absence of ongoing GVHD. 45 Not surprisingly, mature T lymphocyte depletion of allogeneic bone marrow further compromises T cell engraftment and function and is associated with additional delay in immune recovery. 41, 45 There is limited knowledge on immune functions when peripheral blood cells are used as a stem cell source in an allogeneic setting following cytokine mobilization. As previously mentioned, the mobilized product varies vastly from harvested bone marrow as well as normal resting peripheral blood in numbers and function. Mills et al, 16 in addition to reporting increased numbers of T (bearing the ␣␤ and ␥␦ receptor) cells, NK cells and CD45RO + memory cells found that cytokine-mobilized T and B cell products had significantly depressed proliferation and that NKmediated lysis was not increased. G-CSF-mobilized monocytes have been shown to impair and inhibit T cell function in PBSC products and this phenomenon has been attributed to T cell apoptosis achieved by cell to cell contact as well as the elaboration of IL-10 and TNF␣ by monocytes. 49, 50 Furthermore, G-CSF-mobilized monocytes have been shown to inhibit the induction of co-stimulatory molecules like the CD28-responsive complex thus compromising CD4 + T cell function. 51 Since little is known about immune function reconstitution following allogeneic PBSCT with the infusion of 10-50 times more lymphocytes and fourfold more monocytes compared to bone marrow, we evaluated lymphoid engraftment, immune reconstitution and cytokine expression in allogeneic PBSCT recipients during the first 12 months following transplantation.
In our study, NK cell engraftment and function were deficient throughout the first year post allogeneic PBSCT. NK cell numbers were comparatively higher in the first month (although numbers never reached control levels) but subsequently decreased. Functional NK activity remained significantly depressed and showed no evidence of recovery in the period assessed. NK function did not vary at the different time points tested and hence did not seem to be a function of the number of engrafted cells. This is in contrast to conventional BMT recipients who recover NK cell numbers as well as function as early as 1-3 months post transplant. 47, 52 This is of clinical concern since NK cells are cytolytic to virus infected cells and show cytolytic activity against leukemic cell targets. [53] [54] [55] [56] [57] As a result, the risk of viral infections and disease relapse may vary in allogeneic PBSCT recipients compared to those patients undergoing BMT.
The pattern of engraftment of WBCs reflected increased numbers of granulocytes in the first few months post PBSCT. The number of monocytes was stable throughout the first year thus maintaining the same lymphocyte to monocyte ratio and unlikely influenced changes in lymphocyte functions.
We found that the pattern of engraftment of lymphocyte subsets was similar to that reported in traditional BMT recipients. 45 There was persistent reversal of the CD4:CD8 ratio. CD8
+ T cells increased to above baseline levels at 3 months whereas CD4
+ T cell numbers remained low (4.8 at 12 months vs 9.5 ϫ 10 5 /ml in normal premobilization donor controls). The higher numbers of CD8 + T cells resulted in mean lymphocyte counts approaching normal range at 10-12 months post PBSCT. In spite of the mobilization and infusion of mature lymphocyte subsets with a normal CD4:CD8 ratio, 17 CD8 T cells seemed to preferentially engraft in the first year post transplant, similar to that described in recipients following autologous PBSCT. 15 It is unclear whether preferential engraftment of CD8 + T cells is favored by the post-transplant milieu in recipients. Talmadge et al 15 when evaluating recipients of autologous stem cell transplants found early NK cell engraftment but increased levels of 'irradiation resistant suppressor cell' activity as well as increased numbers of TCR ␣␤ CD4 Ϫ , CD8
Ϫ natural suppressor cells post autologous PBSCT. We failed to identify cells with this 'suppressor' phenotype in our recipient population but could demonstrate a lag in mitogenesis similar to the above study. It is possible that the administration of steroids in our recipient population as GVHD prophylaxis resulted in depleting these cells. Persistently low T and B lymphocyte numbers compared to normal controls in the first year is apparent from the analysis described by Beelen et al 58 although in contrast to conventional BMT, CD3 + CD4 + CD45RA cells seem to engraft better along with CD3 + CD4 + CD45RO cells following autologous PBSCT. 20, [58] [59] [60] We found that functional T cell recovery when evaluated by response to standard mitogens (PHA and anti-CD3) as well as allogeneic HLA antigens presented by mixed lymphoblastoid cell stimulators in primary proliferation assays was significantly lower than in normal controls. There was no evidence of recovery in the first year reflecting the persistently low numbers of CD4 + T cells. Defective endogenous IL-2 production by engrafted lymphocytes has also been described as a mechanism that downregulates proliferation to allogeneic antigens in BMT recipients especially in the first 6 months post transplant. 61, 62 Other studies suggest that the addition of exogenous IL-2 or anti-CD3 restores this deficient proliferative response. 63 We were unable to demonstrate a proliferative response to exogenous anti-CD3 or induce a significant PHA response throughout the first year in PBSCT recipients. Keever et al 45 described brisk proliferation early in the first few months post transplant and associated this with the infusion of mature T cells from the donor. In spite of the transfer of significantly higher numbers of functionally competent peripheral T cells we were unable to observe such initial enhanced T cell responses. Antigen presentation by macrophage/monocytes does not seem to be the basis for these immune defects as bypassing antigen presentation still results in persistently low T cell proliferation. A possible mechanism could be inhibition of T cell responses by the increased monocytes present in the infused product 50 or inhibitory cytokines produced by engrafted cells. The presence of acute and/or chronic GVHD also resulted in the continued use of immune suppression in symptomatic recipients. Both these factors, as well as the presence of CMV infection, have been associated with delayed CD4
+ T and B cell engraftment and quantitative differences can influence proliferative responses. 64 Conventional BMT as well as T cell-depleted BMT recipients have demonstrated an inability to respond to anti-CD3 stimulation with increased intracellular calcium. 41 The quantitative decrease in response following BMT has been related to low numbers of specific T cell subsets and low numbers of responding cells, especially CD4 + T cells. 48 B cells have been shown to respond as well as controls. 65 Our patient population had significantly low B cell and CD4 + T cell numbers. Yet, analysis of calcium responses following CD3 cross-linking in PBSCT patients revealed normal intracellular calcium flux indicating that TCR-mediated signalling was intact. Nonspecific responses to anti-CD3 through Fc receptor cross-linking by non-T cells was ruled out by simultaneous analysis using MOPC antibody (data not shown) which showed no increase in intracellular calcium. Our results suggest that even though lymphocyte numbers are low, when evaluated by intracellular Ca 2+ concentration changes post stimulation, engrafted lymphocytes were qualitatively normal.
B cell numbers (CD19 + cells) remained low (less than 50% of control levels) through the first year, yet total immunoglobulin synthesis was comparable at all time points measured to those levels in control B cells following stimulation with PWM at least at 6 days post stimulation. Since conventional protocols recommend this standard period of incubation with PWM, stimulation was not continued beyond this time period. Hence it is unclear whether a longer period of stimulation would have demonstrated a difference in Ig synthesis between normal controls and PBSCT recipients. Higher Ig levels than controls were noticed at one year. Previous studies have demonstrated that following conventional BMT, high IgM responses are present in the first year especially with the development of chronic GVHD. 66 It is possible that a similar IgM increase may be present following PBSCT. This was not separately measured in our assay system. Immunoglobulin secretion in response to PWM stimulation is CD4 + T cell dependent and again demonstrates the functional competence of these cells in spite of low numbers. This method of analysis does not evaluate specific antibody-mediated B cell responses which may be deficient post PBSCT.
Recipient PBMCs constitutively expressed predominantly IL-10 and TNF␣ in the first 6 months post allogeneic PBSCT. This pattern changed to markedly decreased expression of IL-10 in the second half of the first year with continued expression of TNF␣. TNF␣ expression is likely related to the significantly increased numbers of donor monocytes infused although peripheral blood levels did not reflect these monocyte numbers (Table 2) . Mobilized donor cells tend to express more Th2 cytokines (S Shenoy, manuscript in preparation), similar to murine PBMCs mobilized by G-CSF in vivo). 67 The presence of these cells may polarize recipients towards Th2 cytokines in the early post-transplant period. On the other hand, Th2 may predominate secondary to a paucity of Th1 or due to signal transduction deficiencies in such cells. 68 Th1 cytokines IL-2 and IFN␥ are associated with the development of GVHD 69 and propagated by inflammatory cytokines like TNF␣. Th2 cytokines have been associated with protection from GVHD especially in animal BMT models. 70 Consistent with the observed patterns of PBMC cytokine expression and a late decrease in IL-10 expression, a large percent of recipients developed chronic GVHD. 29 IL-10 can also inhibit TNF␣ synthesis by monocytes. 71 The impact of persistent expression of the inflammatory cytokine TNF␣ on acute and chronic GVHD and the influence of other cytokines needs further evaluation post PBSCT.
In keeping with the profoundly compromised T cell and NK cell function, 62% of PBSCT recipients developed CMV viremia in the first year. Some recipients developed multiple viremic episodes and 5.4% developed CMV disease. Immune reconstitution and cytokine profiles in addition to other variables like conditioning and GVHD prophylaxis and treatment are likely to influence the development of such infectious complications and their significance needs to be further evaluated with fairly large randomized trials.
In contrast to our findings, Ottinger et al 46 described early recovery of NK cells and function as well as normal engraftment of lymphocyte subsets (normal CD4:CD8 ratios) by 6 months post PBSCT. T and B cells demonstrated normal proliferation to PHA and PWM, respectively. Adequate proliferative responses to candida and tetanus were also present by 4-6 months. It is unclear whether this difference in immune recovery is related solely to differences in the incidence of GVHD and concurrent immune suppression. Myeloablation protocols can influence the development of GVHD and may influence immune reconstitution. 72 It is unlikely that this difference is age or disease related. Our finding of delayed immune reconstitution as well as changes in cytokine profiles matched clinical GVHD and CMV infection patterns in our recipients.
PBSCT provides an important source of stem cells that has advantages for both donor and recipient. However, immune reconstitution was quantitatively delayed in some areas following allogeneic PBSCT but was qualitatively unimpaired in the group of patients studied. This may provide a clinical difference in GVHD patterns and susceptibility to infectious pathogens compared to conventional BMT. These issues should be explored in patients receiving allogeneic PBSCT as their stem cell source.
